The Patent Reform Act of 2007 is stirring debate, not only in both houses of Congress, but also within the pharmaceutical, biotechnology, software, and electronics industries. Nanotechnology companies too must be aware of what is at stake. In this article, Washington, DC patent attorney Stephen Maebius discusses the potential impact of the pending legislation on nanotechnology. The proposed changes would affect everything from who is entitled to receive a patent (first-to-invent or first-to-file) all the way to how infringement damages are calculated. Because they rely so heavily on the value of their patent portfolio, nanotech companies should form a collective voice to communicate a position in this important debate.
Author(s)
Related Insights
May 30, 2025
Foley Career Perspectives
Foley Mental Health Month Program: Enhancing Performance Through High-Quality Connections
Foley & Lardner endeavors to create a high-performance culture that also prioritizes well-being — a culture where every member of the…
May 29, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence for a contractor convicted of federal wire fraud for misrepresenting use of a disadvantaged business enterprise supplier on a project.